The role of prostate-specific antigen density in men with low-risk prostate cancer suitable for active surveillance: results of a prospective observational study

Klotz, 2013, Prostate cancer overdiagnosis and overtreatment, Curr Opin Endocrinol Diabetes Obes, 20, 204, 10.1097/MED.0b013e328360332a Hayes, 2014, Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence, J Am Med Assoc, 311, 1143, 10.1001/jama.2014.2085 Grasso, 2016, Multicenter analysis of pathological outcomes of patients eligible for active surveillance according to PRIAS criteria, Minerva Urol Nefrol, 68, 237 Schoots, 2015, Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review, Eur Urol, 67, 627, 10.1016/j.eururo.2014.10.050 Jalloh, 2015, Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics, Eur Urol, 67, 451, 10.1016/j.eururo.2014.03.026 D'Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, J Am Med Assoc, 280, 969, 10.1001/jama.280.11.969 Epstein, 2016, The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System, Am J Surg Pathol, 40, 244, 10.1097/PAS.0000000000000530 Thomsen, 2014, Active surveillance for clinically localized prostate cancer--a systematic review, J Surg Oncol, 109, 830, 10.1002/jso.23584 Patel, 2018, Subtyping the Risk of Intermediate-Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy, J Urol, 200, 1068 Bokhorst, 2016, A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment, Eur Urol, 70, 954, 10.1016/j.eururo.2016.06.007 Dong, 2008, Prostate Cancer Volume at Biopsy Predicts Clinically Significant Upgrading, J Urol, 179, 896 Davies, 2011, Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer, J Urol, 186, 2221 Gershman, 2013, Smaller prostate gland size and older age predict Gleason score upgrading, Urol Oncol, 31, 1033, 10.1016/j.urolonc.2011.11.032 Kundu, 2007, Prostate specific antigen density correlates with features of prostate cancer aggressiveness, J Urol, 177, 505 Sfoungaristos, 2013, The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era, Can Urol Assoc J = J l’Association des Urol du Canada., 7, E722, 10.5489/cuaj.374 Magheli, 2010, Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience, J Urol, 183, 126 Corcoran, 2012, The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume, BJU Int, 110, 36, 10.1111/j.1464-410X.2011.10681.x Bul, 2013, Active surveillance for low-risk prostate cancer worldwide: the PRIAS study, Eur Urol, 63, 597, 10.1016/j.eururo.2012.11.005 Gandaglia, 2018, How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator, BJU Int, 10.1111/bju.14391